

PRODUCT INFORMATION

Common Name	CDP-771, CMA-676, WAY-CMA-676,
Synonyms	CD33;SIGLEC3;gp67
Conjugate	Unconjugated
Applications	Flow Cyt
Recommended Dilutions	Flow Cyt 1:100
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Host Species	Humanized
IgG type	Human IgG4 - Kappa
Reactivity	Human
Target	CD33
Uniprot ID	P20138
Description	Anti-CD33 (gemtuzumab biosimilar) mAb
Delivery	In Stock
Storage & Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Usage	Research use only






Figure 1. HEK293 cell line transfected with irrelevant protein (B) and human CD33 (A) were surface stained with anti-CD33 neutralizing antibody 1µg/ml (gemtuzumab) followed by Alexa 488-conjugated anti-human IgG secondary antibody.




Figure 2. Flow cytometry analysis of antigen binding of anti-human CD33 mAb(BME100015). (A) A clear peak shift of BME100015 was seen compared to the control when incubated with CD33-expressing 8226 cells, indicating strong binding of BME100015 to CD33. Antibodies were incubated at 2 µg/mL.






Figure 3. Flow cytometry analysis of antigen binding of anti-human CD33 mAb(BME100015).

(A) BME100015 does not bind to 293T cells that do not express CD33.

(B) A clear peak shift of BME100015 was seen compared to the control when incubated with CD33-expressing THP-1 cells, indicating strong binding of BME100015 to CD33. Antibodies were incubated at 5 µg/mL.

